Pharma-Deko Plc
Fundamental Profile & Historical Analysis · NGX-Listed Equity
₦1.83
▼ 0.20 (9.85%)
Close on 10 Jul 2023 · End of day, Nigerian Exchange · No recent trading: last quote shown
Previous close
₦2.03
Day range
₦1.83 – 1.83
52-week range
₦1.75 – 2.37
Volume
661,645
Value traded
₦1.3m
₦1.83Mon, 10 Jul 2023Volume 662k
Closing prices as published by the Nigerian Exchange, not adjusted for dividends, share splits or consolidations. Daily for the last year, weekly before that.
Returns
| Period | Price | With dividends | Market | Sector |
|---|---|---|---|---|
| 1D | -1.1% | -1.1% | +6.1% | +9.5% |
| 1W | -1.1% | -1.1% | +3.9% | +9.7% |
| 1M | -19.7% | -19.7% | +15.2% | +40.9% |
| 3M | -3.2% | -3.2% | +21.6% | +52.3% |
| 6M | -12.9% | -12.9% | +25.2% | +50.0% |
| YTD | -12.9% | -12.9% | +25.7% | +58.8% |
| 1Y | — | — | +24.5% | +36.5% |
| 3Y | — | — | +164.4% | +186.4% |
| 5Y | -16.8% | -16.8% | +66.0% | +39.5% |
Price returns use closes adjusted for splits and consolidations. “With dividends” adds back cash dividends. Market and sector are TickerNG's own market-cap-weighted price indices built from NGX closes and share counts; they are not NGX's All-Share Index.
Risk and liquidity
Worst fall, 5 years
-38.5%
Below its high now
-29.6%
Volatility, 1 year
54.6%
Beta vs market
-0.43
Avg daily volume, 3 months
659,914
Days traded, last 63
63
The worst fall ran from Oct 2021 to Apr 2022 and has not regained its peak.
From split-adjusted closes, without dividends. Beta is against TickerNG's own market index (not NGX's), from weekly moves over 71 weeks.
Dividend history
No payment this year or last · paid in 1 of the last 10 years
| Year | Per share | Payments |
|---|---|---|
| 2018 | ₦0.05unconfirmed | final |
Cash dividends in naira, by the year of the ex-dividend date, from NGX corporate notices. Not a forecast.
Versus healthcare peers
PHARMDEKO among 7 listed companies in the sector
| Measure | PHARMDEKO | Peer median | Rank | Ahead of |
|---|---|---|---|---|
| Market cap | ₦0bn | ₦52bn | 7 of 7 | — |
Only companies with the figure are counted. With fewer than five, no percentile is shown. A cheaper P/E is not by itself a better company.
Valuation, with your assumptions
Change any assumption and the values follow. Defaults: the required return is the latest 364-day T-bill stop rate plus 5 points; growth is PHARMDEKO's own dividend growth where it has a record.
Dividend discount
₦0.32
-83% vs price
Starts from ₦0.05 a share (2018 payments).
Discounted earnings
—
Needs positive earnings per share.
Peer multiples (healthcare)
—
P/E at the peers' quartiles. Peers are not identical businesses.
These are tools for testing a view, not forecasts or advice. A result is only as sound as the assumptions: the dividend model needs a steady payer, and earnings are not cash. A blank value means the inputs cannot give one (for example a required return at or below growth).
TickerNG provides research and information only. Nothing here is a recommendation to buy, sell or hold any security, and TickerNG is not a licensed investment adviser or broker. Figures are taken from company filings and market data and may be incomplete, delayed or restated, so check them against the linked source. Reports are generated with AI from that data and can contain errors. Past performance does not predict future results, and you can lose money. Make your own decision, or speak to a licensed adviser. Terms
Run a live verification on PHARMDEKO
Multi-specialist AI analysis — fundamentals, news, macro, sentiment, and a contrarian challenge — synthesised into a sourced investment thesis.
Verify PHARMDEKO on TickerNG →Free tier available. No credit card required.